Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of oral ICP-332 in adolescents with moderate to severe atopic dermatitis
CTR20261421Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soficitinib in atopic dermatitis (AD), sponsored by InnoCare Pharma. Started Jun 2026; status: active.
02
Drugs
soficitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20261421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261421.